HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

bivalirudin (Angiomax)

Subscribe to New Research on bivalirudin

designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition

Also Known As:

Angiomax; BG 8967; BG-8967; BG8967; Hirulog; Hirulog-1; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); The Medicines Company brand of bivalirudin; L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-

Networked: 652 relevant articles (106 outcomes, 211 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Mehran, Roxana: 73 articles (11/2015 - 09/2005)
2.	Stone, Gregg W: 71 articles (04/2015 - 09/2005)
3.	Lincoff, A Michael: 39 articles (05/2014 - 05/2002)
4.	White, Harvey D: 32 articles (03/2015 - 02/2002)
5.	Feit, Frederick: 27 articles (12/2014 - 02/2003)
6.	Lansky, Alexandra J: 25 articles (02/2015 - 05/2006)
7.	Ohman, E Magnus: 23 articles (12/2014 - 09/2004)
8.	Waksman, Ron: 23 articles (09/2014 - 11/2003)
9.	Witzenbichler, Bernhard: 21 articles (02/2015 - 05/2008)
10.	Parise, Helen: 21 articles (12/2014 - 05/2008)

Related Diseases

1.	Hemorrhage 12/01/2013 - "Bivalirudin was associated with a dramatically reduced risk of bleeding across all categories of renal dysfunction. " 03/01/2013 - "The primary purpose of this analysis is to evaluate the hypothesis that the reduction of in-hospital bleeding is the most plausible explanation for the improved survival of STEMI patients treated with bivalirudin during primary PCI. " 12/01/2005 - "Bivalirudin provides excellent ischemic protection with a significant reduction of bleeding complications, even in high-risk subgroups." 06/01/2004 - "These results suggest that bivalirudin may be used effectively in patients at very high risk of bleeding with enhanced procedural safety." 05/01/2015 - "In present meta-analysis, among patients undergoing PCI, bivalirudin, as compared with UFH, is associated with a significant reduction in major bleeding complications that, however, does not translate into mortality benefits. "
2.	Acute Coronary Syndrome 08/01/2009 - "The objective was to assess the safety and efficacy of bivalirudin monotherapy in patients with high-risk acute coronary syndrome (ACS) presenting to the emergency department (ED). " 01/01/2008 - "In summary, is has been shown that bivalirudin alone is safe and effective in the vast majority of patients suffering from acute coronary syndromes and being treated invasively. " 01/01/2012 - "Randomized trials show improved outcomes among acute coronary syndrome patients treated with bivalirudin. " 01/01/2008 - "Recent trials (ACUITY and HORIZONS studies) added evidence regarding safety and efficacy of bivalirudin use in acute coronary syndromes. " 01/01/2008 - "Safety and efficacy of bivalirudin in acute coronary syndromes."
3.	Myocardial Infarction 01/01/2012 - "Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database." 12/01/2014 - "The effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention for acute myocardial infarction has been tested in clinical trials, but its use in a real-world scenario has never been reported. " 09/21/2014 - "In the EUROMAX study, 2198 patients with ST-segment elevation myocardial infarction (STEMI) were randomized during transport for primary PCI to bivalirudin or to heparins with optional GPI. " 10/01/2013 - "Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial." 04/01/2012 - "Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial."
4.	Thrombosis (Thrombus) 10/01/2008 - "In the bolus bivalirudin group the mean thrombus weight was significantly greater than in all other groups (p-value < 0.01 in all analyses). " 03/01/2015 - "The present study showed similar residual thrombus burden and angiographic indices of MVO immediately after PCI between patients treated with bivalirudin and those treated with UFH." 08/01/2007 - "Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis." 03/01/2015 - "Patients in the bivalirudin group showed lower proportion of white thrombus (55.5% vs. 78.6%, P = 0.016). " 03/01/2015 - "Patients treated with bivalirudin showed similar thrombus volume (0.14 mm(3) [0.00-0.88] vs. 0.13 mm(3) [0.00-0.63], P = 0.962), thrombus score (10 [0-25] vs. 8 [0-21], P = 0.849) and thrombus length (1.70 mm [0.00-4.10] vs. 1.40 mm [0.00-4.05], P = 0.968], as compared with patients treated with UFH. "
5.	Unstable Angina 03/01/2002 - "In this preliminary study, the strategy of bivalirudin bolus anticoagulation, immediate sheath removal, and 2-hr ambulation after PCI appeared safe, with same-day discharge possible in 26% of unselected patients with stable or unstable angina." 01/01/2002 - "Data from dose-finding studies indicate bivalirudin has potential in the treatment of patients with unstable angina not undergoing percutaneous coronary intervention (PCI); however, well designed comparative studies are needed before firm conclusions can be made. " 08/15/1995 - "Hirulog in the treatment of unstable angina. " 10/01/1993 - "In unstable angina patients, Hirulog infusions quickly and reproducibly yield stable, dose-dependent anticoagulant and antithrombotic effects with a favorable clinical efficacy profile." 10/01/1993 - "A total of 55 patients in the acute phase of unstable angina received intravenous Hirulog according to one of two protocols. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Glycoproteins (Glycoprotein)
3.	Thrombin
4.	Platelet Membrane Glycoprotein IIb
5.	clopidogrel (Plavix)
6.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
7.	bivalirudin (Angiomax)
8.	Enoxaparin (Lovenox)
9.	Hirudins
10.	Antithrombins

Related Therapies and Procedures

1.	Stents
2.	Angioplasty (Angioplasty, Transluminal)
3.	Drug Therapy (Chemotherapy)
4.	Transplants (Transplant)
5.	Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)